Margaret Dugan's most recent trade in BeiGene Ltd - ADR was a trade of 22,750 Share Option (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BeiGene Ltd - ADR | Margaret Dugan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 22,750 | 22,750 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Margaret Dugan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 10,985 | 56,940 (0%) | 0% | 0 | Ordinary Shares | |
| Schrodinger Inc | Margaret Dugan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Schrodinger Inc | Margaret Dugan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 12,500 | 25,969 (0%) | 0% | 0 | Common Stock | |
| Schrodinger Inc | Margaret Dugan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.78 per share. | 15 Oct 2024 | 1,531 | 13,469 (0%) | 0% | 17.8 | 27,226 | Common Stock |
| BeiGene Ltd - ADR | Margaret Dugan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 34,151 | 34,151 | - | - | Share Option (Right to Buy) | |
| BeiGene Ltd - ADR | Margaret Dugan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 16,341 | 45,955 (0%) | 0% | 0 | Ordinary Shares | |
| Schrodinger Inc | Margaret Dugan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) |